Introduction
Retigabine is an antiepileptic drug (AED) with a novel mechanism of action that involves positive allosteric modulation of KCNQ2-5 (Kv7.2-7.5) ion channels, causing hyperpolarization and reduced high-frequency action potential firing. Based on data from clinical trials [1] [2] [3] , retigabine was approved for the adjunctive treatment of patients with partial-onset seizures (POS) aged ≥ 18 years in the United States of America (USA) and Europe (EU) in 2011 [4, 5] and was commercially available from 2011 in EU [4] and May 2012 in the USA (as 'ezogabine') [6] . However, following reports of discoloration of the nails, lips, skin, and/or mucosa and pigmentation of ocular tissues, including the retina, in some patients receiving retigabine [7] , the indication was restricted in 2013. In the EU, the indication changed to adjunctive treatment of drug-resistant POS, where other appropriate drug combinations have proved inadequate or have not been tolerated [8] . In the USA, the indication was updated to adjunctive treatment of POS in patients who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity [5] . There were also other significant labelling changes, including additional Warnings and Precautions, and the requirement for 6-monthly comprehensive eye examinations to align postmarketing findings with those in clinical trials.
Patients who completed any of the four pivotal retigabine clinical trials were given the opportunity to continue treatment with retigabine in open-label extension studies. At the time of the label change in 2013, there were four ongoing safety extension studies. Following the restriction in the indication, these extension studies were amended to include enhanced safety monitoring in the form of 6-monthly comprehensive ophthalmological assessments and regular dermatological examinations. A final nontreatment long-term safety follow-up continuation phase was also offered to those who experienced retinal pigmentation, unexplained vision loss, pigmentation of nonretinal ocular tissue, or abnormal discoloration of skin, lips, nails, and/or mucosa while receiving retigabine to evaluate if pigmentation/discoloration events worsened, persisted, stabilized, or resolved when retigabine was stopped.
In 2015, as a result of the additional comprehensive eye examinations, a new adverse drug reaction, acquired vitelliform maculopathy (AVM), was identified. This led to a further change to the EU label, which recommended inclusion of fundus photography and ocular coherence tomography (OCT) as tools to be used as part of the regular eye examinations as well as the requirement that patients with maculopathy should be closely monitored and the benefits of continued treatment carefully weighed against the risks [9] . In 2016, GlaxoSmithKline took the decision to voluntarily withdraw retigabine/ezogabine from the worldwide marketplace because of its limited usage. Following several months' notice, all retigabine treatment in patients participating in the open-label extension studies was stopped; all investigators were advised to ensure that all patients were no longer receiving retigabine by the end of March 2017. Similarly, following~1 years' notice to healthcare professionals, to allow alternative therapy to be identified, retigabine/ezogabine was withdrawn from the worldwide market at the end of June 2017. Follow-up in the safety follow-up continuation phase was continued to monitor patients with abnormal skin and eye findings after discontinuation of retigabine.
Several nonclinical investigations were conducted to determine the nature and mechanism of the discoloration/pigmentation in patients taking retigabine [10, 11] . Although other potential mechanisms of discoloration, including a potential increase in melanogenesis, metal chelation, involvement of an excipient (indigo carmine), or an active pharmaceutical ingredient impurity, have been considered, data from nonclinical investigations [11, 12] and the analysis of clinical biopsy samples from areas of discoloration from patients taking retigabine support a primary hypothesis that the discoloration may involve the accumulation of free or melanin-bound pigmented retigabine-related material.
We report data from four individual open-label extension studies of retigabine focusing on ophthalmological and dermatological findings from each study and including data from the safety follow-up continuation phase. 
Materials and methods

Study design
Parent studies
The methodologies of the parent studies have been reported previously [1, 2, 13, 14] . Briefly,
• RGB113905 (NCT01227902), the parent of study 113413, was an open-label study of flexibly dosed retigabine as an adjunct therapy to one of 4 AEDs comprising a 4-week titration phase and a 16-week flexible-dose evaluation phase [13] . • RTG114855 (NCT01777139), the parent of study 114873, was a randomized, double-blind study of retigabine 600 or 900 mg/day versus placebo in adult Asian patients with drug-resistant POS receiving 1-3 AEDs, with a 4-week titration phase and 12-week treatment phase [14] . • RESTORE-2 (VRX-RET-E22-302; NCT00235755), the parent of study 115097, was a randomized, double-blind, placebo-controlled trial in adults with ≥4 POS/month receiving 1-3 AEDs, in which retigabine was titrated to 600 or 900 mg/day over 4 weeks and continued during a 12-week maintenance phase [2] . • RESTORE-1 (VRX-RET-E22-301; NCT00232596), the parent of study 115098, was a randomized, double-blind, placebo-controlled study in adults with ≥4 POS/8 weeks who were receiving 1-3 AEDs, with a 6-week forced dose-titration phase to retigabine 1200 mg/day followed by a 12-week maintenance phase [1] .
Open-label extension studies
For studies 114873, 115097, and 115098, for which the parent studies were double-blind, a transition phase was included prior to beginning open-label treatment in order to maintain the double-blind status of the parent studies. During the transition phase, retigabine was titrated/maintained so that all patients were receiving one of three dosages, 750 mg/day (study 114873), 900 mg/day (studies 114873 and 115097), and 1200 mg/day (study 115098). Patients entering study 113413, for which the parent study was open-label, attended a screening visit on the same day as the final visit of the parent study and remained on their current dose. During open-label treatment in the extension studies, the dose of retigabine could be altered to meet the efficacy and tolerability needs of the patients; however, the overall daily dosage was to be maintained at 300-1200 mg/day (study 113413) or 600-1200 mg/day (studies 114873, 115097, and 115098).
Concomitant AEDs were permitted during the extension studies, and after entering open-label treatment (or following 1 week of open-label treatment in studies 113413 and 114873), investigators could adjust AED doses or add or switch to a new AED (with the exception of vigabatrin in all studies and felbamate in studies 114873, 115097, and 115098). In study 113413, all patients received a single concomitant AED in accordance with the protocol and parent study, and thus, retigabine monotherapy was not permitted. Therefore, if concurrent AED treatment was removed, the patient was withdrawn from the study. In contrast, in studies 115097 and 115098, investigators could discontinue all background AEDs to achieve monotherapy with retigabine, if clinically appropriate.
Including the baseline visit, there were 5, 6, 10, and 10 visits during the first year in studies 113413, 114873, 115097, and 115098, respectively; visits occurred every 4 months from year 2 onwards.
Safety follow-up continuation phase
A protocol amendment was introduced to include a safety follow-up continuation phase after the sponsor became aware of pigmentation/ discoloration events experienced by some patients receiving retigabine, with the purpose of monitoring pigmentation/discoloration events after the patients had finished retigabine therapy. The safety follow-up continuation phase consisted of selected safety assessments approximately every 6 months after retigabine discontinuation until pigmentation/discoloration had been assessed to be resolved or stable over 12 months on 2 consecutive assessments obtained ≥6 months apart.
Study termination
Following the decision to withdraw retigabine from the market, studies were considered complete once all patients had withdrawn from the safety follow-up continuation phase because all events had either resolved or were stable. However, study 115097 was terminated with 2 patients still in safety follow-up, with the rationale that collecting further data would no longer be of any benefit. These patients had stopped retigabine treatment over 12 months prior to study termination, and although they had not yet met the protocol-defined study termination criteria, they had experienced improvements in pigmentation.
Ethics approval
The study protocols and amendments were reviewed and approved by a national, regional, or investigational center ethics committee or institutional review board in accordance with the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and applicable country-specific requirements. The studies were conducted in accordance with the ethical principles that are outlined in the Declaration of Helsinki 2004/2008, and all patients provided written informed consent.
Patients
Patients who completed their parent study and whom the investigator believed may benefit from continued therapy with retigabine were eligible to enter the respective open-label extension study. For studies 113413 and 114873, patients with any clinically significant abnormal laboratory or electrocardiogram findings not resolved prior to entry to the open-label extension were excluded. For studies 115097 and 115098, patients with any ongoing serious adverse event (SAE) were excluded. For all four studies, patients were excluded if they had any medical condition that, in the investigator's judgment, was considered to be clinically significant and could have potentially affected patient safety or compliance with study procedures.
Any patient who withdrew from the open-label treatment phase prior to the protocol amendment to include the safety follow-up continuation phase and who had abnormal retinal pigmentation or unexplained vision change, pigmentation of nonretinal ocular tissue, or abnormal discoloration of skin, lips, nails, and/or mucosa at the time of withdrawal was asked to enter the safety follow-up continuation phase.
Study objectives
The primary objective of the four open-label extension studies was to assess the long-term safety and tolerability of retigabine in adults with epilepsy and POS. Evaluation of the long-term efficacy of retigabine was a secondary objective in all four studies. Following the protocol amendments in 2013, assessment of change over time in retinal pigmentation, unexplained vision loss, pigmentation of nonretinal ocular tissues, and discoloration of nails, lips, skin, and/or mucosa after discontinuation of retigabine was included as a secondary objective in all four studies.
Study assessments
Safety
General safety assessments conducted throughout the open-label treatment period included monitoring treatment-emergent adverse events (TEAEs) and SAEs. Treatment-emergent adverse events were defined as adverse events (AEs) for which the onset was on or after the date of the first retigabine dose in an open-label extension study and on or before 30 days after the date of the last retigabine dose. In addition, a postvoid residual (PVR) bladder ultrasound to assess urinary retention was performed at baseline and after 1, 3, and 12 months then annually and at study termination.
Following the identification of pigmentation/discoloration events, protocol amendments required the evaluation of AEs of special interest (AESIs) of retinal pigmentary abnormalities and/or vision loss, pigmentation of nonretinal ocular tissues, and discoloration of nails, lips, skin, and mucosa.
In addition, following the protocol amendment, extensive retigabinespecific ophthalmic examinations and ancillary tests (see Supplementary materials) were required for patients to continue retigabine treatment. These examinations/tests were developed in consultation with an ophthalmologist and retinal specialist (focusing on potential findings of the eye including changes in retinal pigmentation, unexplained vision loss, and pigmentation of nonretinal ocular tissue) and completed by an ophthalmologist for each patient approximately every 6 months. Furthermore, following the identification of AVM as a new adverse drug reaction to retigabine, the sponsor implemented a broad search strategy "maculopathy" to review TEAE data in order to identify potential cases.
Dermatological examinations (nails, lips, skin, and mucosa) were performed by the investigator at each visit and followed up approximately every 6 months by a dermatologist where retigabine-related abnormal discoloration was confirmed. Optional tissue biopsies were requested following the 2013 protocol amendment to investigate possible causes of discoloration. Histopathological analyses included hematoxylin and eosin, Fortana-Masson, Perls' Prussian Blue, and Periodic acid-Schiff. In addition, samples were analyzed for Melan-A immunohistochemistry. Formalin-fixed paraffin-embedded unstained sections from tissue of clinical biopsy samples from some patients with discoloration were analyzed for the presence of retigabine-related material (including retigabine-retigabine and N-acetyl metabolite of retigabine [NAMR]-NAMR dimers).
Efficacy and quality of life
Efficacy endpoints included percentage change from baseline in 28day POS frequency, as assessed by a daily seizure diary completed by the patient. Quality of life was evaluated in studies 115097 and 115098 using the Quality of Life in Epilepsy (QOLIE)-31-P (version 2.0) questionnaire, which was also completed by the patients.
Safety follow-up continuation phase assessments
During the safety follow-up continuation phase, assessments included monitoring AEs related to discoloration/pigmentation of the eye/skin, SAEs and deaths, and 6-monthly eye and/or skin examinations.
Statistical analyses
All analyses were performed in the safety population (patients who received ≥ 1 dose of retigabine in the open-label phase) or the safety follow-up population (all patients who entered the safety follow-up continuation phase).
Assessment outcomes are presented using descriptive statistics. Baseline demographics data were collected in the parent study, with the exception of age. For safety assessments, baseline data were defined as either those collected during the last assessment in the parent study prior to the first retigabine treatment (115097 and 115098) or those collected during the parent study baseline period (113413). For study 114873, baseline data were those collected during the parent study baseline period for patients who received active treatment in the parent study or data from the last maintenance phase visit of the parent study for patients who received placebo in the parent study. For efficacy assessments, baseline data were defined as those collected during the parent study baseline period. As skin and eye examinations were introduced during the open-label treatment phase in each extension study, there were no pre-retigabine baseline data.
Results
Patients
All patients enrolled in the extension studies received at least one dose of retigabine and were included in the safety population, 98 in study 113413, 30 in study 114873, 376 in study 115097, and 181 in study 115098 ( Fig. 1 ). Baseline demographics are summarized in Table 1 . The mean age across the studies (total populations in each study) ranged from 36 to 39 years, and the mean duration for which patients had experienced POS ranged from 22 to 24 years (data from studies 115097 and 115098 only). In studies 114873, 115097, and 115098, the majority of patients were receiving ≥1 AED at open-label baseline (97%, 100%, and 100%, respectively). The percentages of patients receiving 1, 2, or 3 AEDs at open-label baseline in these studies are shown in Supplementary Table 1 . In study 113413, in which patients had been recruited from the open-label parent study, all patients received 1 AED at baseline as per the protocol. The majority (86%) stayed on their existing AEDs, while 14% of patients switched to or added a new AED.
Mean (standard deviation) exposure to retigabine (including the taper phases) was 1129 (999) days in study 115098, 801 (538) days in study 113413, 529 (424) days in study 114873, and 926 (940) days in study 115097 (mean and median exposure data are shown in Supplementary Table 2 ). Reasons for discontinuation are summarized in Table 2 (with data stratified by parent study treatment group shown in Supplementary Table 3 ). The percentage of patients discontinuing the studies because of AEs ranged from 17%-28%, and 0%-22% of patients discontinued because of switching to commercial retigabine. In addition, 60%-77% discontinued because of other reasons, including unsatisfactory efficacy response, being unwilling or unable to continue the study, or being lost to follow-up.
Safety
General safety assessments
The percentage of patients experiencing any TEAE ranged from 68% (in study 113413) to 96% (in study 115098). The most common TEAEs in each study are shown in Table 3 . Dizziness was the most common TEAE across all studies, occurring in 14%-40% of patients. Treatment-emergent SAEs are also shown in Table 3 . Overall, 4%-27% of patients across studies experienced treatment-emergent SAEs. The number of treatment-emergent SAEs thought to be related to retigabine was 14 (8%) in study 115098, 1 (1%) in study 113413, 0 in study 114873, and 34 (9%) in study 115097. The only treatmentemergent SAEs considered related to retigabine that occurred in N 2 patients in any study were seizure, epilepsy, confusional state, urinary retention, and retinal pigmentation.
All subjects (safety population)
113413: Postvoid residual (PVR) bladder ultrasound category shifts from baseline to maximum postbaseline categories for studies 113413, 115097, and 115098 are shown in Supplementary Table 4 . Overall, the majority of patients (49%-80% across these studies) had baseline PVR volume of ≤50 mL (which is within normal ranges [15] ) and remained in that category throughout the studies. In study 114873, the mean PVR volume was b 40 mL across all scheduled visits. Across all studies, a total of 23 patients had a TEAE of urinary retention.
One patient in study 115098 and 7 patients in study 115097 died during the open-label treatment phase; of these, 4 patients had AEs that were considered possibly related to retigabine by the investigator (cellulitis and septic shock in one patient, plasma cell myeloma in one patient, and sudden unexplained death in epilepsy in 2 patients, all from study 115097). Further safety data for each trial are available on www.clinicaltrials.gov.
Ophthalmological investigations
Ophthalmological abnormalities are summarized in Table 4 . Overall, 14%-73% of patients had an on-treatment eye examination, of whom 43%-73% were reported to have an ophthalmological abnormality. Clinically significant decrease in visual acuity was uncommon (6%-16% of patients) and in most cases could be explained by cataract, senile changes, glaucoma, or diabetic retinopathy.
Abnormal retinal pigmentation was reported in 8/53, 4/22, 17/54, and 14/36 patients with an ophthalmological examination in studies 113413, 114873, 115097, and 115098, respectively. The median time from initiation of retigabine in the parent study to first detection of retinal pigmentation ranged from 1.67 years (study 114873) to 6.31 years (study 115097).
Retinal pigmentation was reported as an AESI in 5 (5%), 2 (7%), 12 (3%), and 12 (7%) of patients in studies 113413, 114783, 115097, and 115098; these led to discontinuation in 1 (1%), 0, 4 (1%), and 6 (3%) patients, respectively.
Nonretinal ocular pigmentation was reported in 15/53, 7/22, 15/54, and 11/36 patients with an ophthalmological examination in studies 113413, 114873, 115097, and 115098, respectively. The median time from initiation of retigabine in the parent study to first detection of Abbreviations: alanine aminotransferase (ALT), aspartate aminotransferase (AST), case report form (CRF), upper limit of normal (ULN). a Percentages not provided as only patients who used CRFs revised after protocol amendment have data. b Other reasons included unsatisfactory efficacy response, pregnancy, unwilling/unable to continue study/withdrawal of consent, noncompliant with study procedures/protocol deviation, clinically significant change in medical condition, persistent ALT/AST levels N3× ULN, ALT/AST levels N5× ULN, withdrawal in best interest of the patient in investigator's opinion, request from study sponsor, failure to return/loss to follow-up, patient request unrelated to study, study closed/terminated, and other event. c One patient was missing a primary reason for withdrawal. nonretinal ocular pigmentation ranged from 0.35 years (study 114873) to 6.20 years (study 115097).
Nonretinal ocular pigmentation was reported as an AESI in 8 (8%), 0, 2 (b 1%), and 4 (2%) of patients in studies 113413, 114783, 115097, and 115098, respectively; these led to discontinuation in 2 (2%), 0, 0, and 1 (b1%) patients, respectively.
A broad search of AE data for the AESI of maculopathy (comprising 45 preferred terms) identified 9, 4, 26, and 23 patients in studies 113413, 114783, 115097, and 115098, respectively, who had an AESI of maculopathy, 8, 2, 20, and 14 of whom potentially had AVM based on their AE data; AVM was not confirmed in any patient following internal and external expert review of available data.
Expert review of the macular OCT tests identified four patients with confirmed AVM.
Dermatological investigations
Treatment-emergent AESIs of skin discoloration or dermatologistconfirmed abnormal discoloration are shown in Table 5 , with photographic examples shown in Fig. 2 .
Overall, 12%-83% of patients had an on-treatment dermatological examination, of whom 0%-62% were reported to have dermatologistconfirmed abnormal discoloration. The most common types of dermatologist-confirmed abnormal discoloration were discoloration of the nails (17%-57%) and of sun-exposed tissue (17%-59%). The median time from initiation of retigabine in the parent study to first occurrence of dermatologist-confirmed abnormal discoloration was 2.43 (0.9-3.2) years, 6.63 (0-9.3) years, and 5.37 (0.7-8.8) years in studies 113413, 115097, and 115098, respectively (no patients in study 114873 experienced dermatologist-confirmed abnormal discoloration). During studies 115097 and 115098, 11 and 7 tissue biopsy samples of discolored skin from 4 and 6 patients were taken and analyzed, respectively. The biopsy samples exhibited similar staining patterns. Based on review by the consultant dermatopathologist, the staining of the pigmented tissue deposits was not consistent with hemosiderin or mucopolysaccharides but was indicative of the presence of a reducing agent.
Overall, 3%-23% of patients reported an AESI of skin discoloration. Table 6 . In total, 3, 3, 13, and 7 patients in studies 113413, 114873, 115097, and 115098, respectively, had on-treatment abnormal retinal pigmentation. Of these, 3, 3, 10, and 7 patients had ≥1 posttreatment evaluation, and in 1, 0, 0, and 1 of these, retinal pigmentation had resolved completely. The time taken from retigabine discontinuation to resolution was 157 days in study 113413 and 317 days in study 115098. Unresolved on-treatment abnormal nonretinal ocular pigmentation after stopping therapy occurred in 4, 3, 11, and 6 patients who agreed to enter the safety follow-up continuation phase in studies 113413, 114873, 115097, and 115098, respectively. At least one posttreatment evaluation was available in 4, 3, 10, and 6 patients, respectively, and abnormal nonretinal ocular pigmentation resolved completely in 1, 0, 8, and 4. The median number of days between retigabine discontinuation and resolution of the abnormal pigmentation in these patients ranged from 119 to 312 days.
Of the patients with clinically significant decreases in visual acuity in the open-label treatment phase, 0/3, 1/3, 4/5, and 1/2 from studies 113413, 114783, 115097, and 115098 entered the safety follow-up continuation phase, respectively. Of these, visual acuity remained constant in the patients from studies 114783 and 115098 and in 2 of the patients from study 115097. Of the remaining 2 patients from study 115097, the decrease in visual acuity continued in one patient because of mild cataracts, while the other experienced an improvement in visual acuity because of cataract surgery.
Of the patients with a decrease in confrontation visual field during the open-label treatment phase, 0/1, 1/4, and 3/5 from studies 113413, 114783, and 115097 entered the safety follow-up continuation phase (no patient in study 115098 experienced a decrease in confrontation visual field), respectively. All patients continued to have abnormal confrontation visual field throughout the safety follow-up. N, number of patients with ≥1 ophthalmology examination on or before last dose of retigabine, except *patients with both initial and ≥1 follow-up examination while on retigabine. a Endpoints pertaining to ophthalmological abnormalities (it is possible that other ophthalmological abnormalities that are not endpoints occurred). 
Dermatological follow-up.
Dermatologist-confirmed abnormal discoloration after discontinuation of retigabine is shown in Table 6 .
Of patients with unresolved dermatologist-confirmed tissue discoloration after stopping therapy in the open-label treatment phase, 3, 15, and 11 in studies 113413, 115097, and 115098, respectively, agreed to enter the safety follow-up continuation phase (no patients in study 114873 experienced dermatologist-confirmed tissue discoloration). At least one posttreatment evaluation was available in 3, 13, and 11 of these patients, and tissue discoloration completely resolved in 2, 7, and 1, respectively. The median period between retigabine discontinuation and resolution of tissue discoloration in these patients ranged between 380 and 582 days.
3.2.4.3. Adverse events. Adverse events assessed during the safety followup (i.e., AEs related to discoloration/pigmentation of the eye/skin, SAEs, and deaths) were reported by 3, 0, 4, and 0 patients in studies 113413, 114783, 115097, and 115098, respectively. Three SAEs were reported (one in study 113413 [breast cancer] and 2 in study 115097 [gastrointestinal necrosis and sudden unexplained death in epilepsy]), one of which was considered to potentially be treatment-related (breast cancer). In addition, one patient in study 115097, who did not enter the safety follow-up continuation phase, died of asphyxia during an epileptic seizure 52 days after stopping retigabine treatment. This death was not considered to be treatment related.
Efficacy and quality of life
Change from baseline to end of open-label treatment in 28-day total partial seizure frequency is shown in Table 7 . The median percentage change in frequency ranged from -40.9% in study 114873 to -71.8% in study 113413. Further efficacy data and data on patient quality of life assessed using QOLIE-31-P in studies 115097 and 115098 are available on www.clinicaltrials.gov.
Discussion
Four open-label extension studies in adults with epilepsy and POS were designed to characterize the long-term safety and tolerability of adjunctive retigabine therapy. In general, the safety profile of retigabine across these four studies was consistent with the known safety profile established throughout the clinical trial program [1, 2, 13, 14] . Following completion of the parent studies and while the open-label extensions of these studies were ongoing, discoloration of the skin, lips, nails, and mucosa was observed in a subset of patients, as were retinal and nonretinal ocular pigmentation. Furthermore, following implementation of comprehensive eye examinations and ancillary tests, four patients with features of AVM were identified.
In terms of general safety observations, dizziness was the most common TEAE across all four extension studies, as was the case in the parent studies [1, 2, 13, 14] . Urinary retention had been identified during development and was reported as an AE in each of the four parent studies [1, 2, 13, 14] . Mechanistically, retigabine has a pharmacological effect on the KCNQ (K v 7) channels in urinary bladder smooth muscle, which may lead to inhibition of bladder contractility and urinary retention [16] . Consequently, the protocol for the extension studies included PVR bladder ultrasound investigations. Across the four extension studies, the majority of patients had baseline PVR volumes within normal ranges (≤50 mL) [15] , which remained within these ranges throughout their respective studies.
The incidence of at least one eye ophthalmological abnormality reported in these studies is somewhat higher (43%-73%) than the incidence of visual abnormalities in the general epilepsy population, which is reported to be between 20% and 45% [17] [18] [19] . However, it is difficult to know whether this difference is attributable to retigabine treatment or a refractory epilepsy population in the absence of preretigabine baseline ophthalmological data, or potential bias in that these patients are a subset of the study population and only a low proportion of them had eye examinations. Retinal pigmentation, specifically, was reported as an AE in between 3% and 7% of patients across the four studies and nonretinal ocular pigmentation in between 0% and 8% of patients. The median time from initiation of retigabine treatment to first detection of pigmentation ranged, broadly, from 1.5 to 6 years in the case of retinal pigmentation and 0.5 to 6 years for nonretinal ocular pigmentation. This is not entirely surprising considering that studies 113413 and 114783 were initiated much later than 115097 and 115098; in these later studies, pigmentation-related events were actively sought and therefore likely identified earlier in the course of treatment. Finally, as a result of the additional comprehensive eye examinations and required ancillary tests conducted within the primary clinical trials, AVM was identified as a new adverse drug reaction in 2015, and four cases have been confirmed in the clinical development program. To our knowledge, no published data are available on ocular or retinal pigmentation in epilepsy; however, both permanent and reversible structural changes in the retina have been observed in patients with epilepsy receiving certain antiepileptic medications [20] .
In addition to ophthalmological abnormalities leading up to the 2013 restriction in indication, some patients reported discoloration of the nails, lips, skin, and/or mucosa. These discoloration events appear to be associated with pigmented retigabine-related material, as found in nonclinical studies, which might help to explain the delayed onset of the events and the association with long-term use [10, 12] . Abnormal eye pigmentation and dermatologist-confirmed abnormal discoloration unresolved at the time of discontinuation of retigabine (safety follow-up population).
Although patient numbers in the safety follow-up continuation phase were small, the results provided valuable information regarding the potential for resolution of pigmentation/discoloration events following discontinuation of retigabine treatment. Results suggest that pigmentation/ discoloration may resolve following treatment discontinuation in some patients with retinal, nonretinal, and/or ocular pigmentation.
There are a number of study limitations to consider when interpreting these important safety data. First, there were low patient numbers at later timepoints when the amendments in the open-label extension studies were implemented to evaluate the skin and eye findings and in the safety follow-up continuation phase. Second, there was no comparator to provide a point of reference to determine causality for the dermatologic and ophthalmologic events observed. Moreover, as ophthalmological and dermatological tests were introduced after the studies had been initiated, there were no pre-retigabine baseline data to compare with the on-treatment data. Finally, there is the possibility that the selection of participants for each of the open-label extension study populations was biased towards patients who experienced treatment benefits and favorable tolerability with retigabine, as those with a lack of efficacy or those who had experienced AEs are likely to have discontinued the parent studies or elected not to continue into their respective open-label extension study. Despite these limitations, the studies provide important information regarding the long-term safety and tolerability of retigabine in patients with POS and the potential for resolution of pigmentation/discoloration events following treatment withdrawal.
Conclusions
In conclusion, the safety profile of retigabine in adults with POS across four open-label studies was generally consistent with data from previous placebo-controlled studies. Discoloration of various tissues occurred in a proportion of patients treated with retigabine and resolved in a small number of these patients following treatment discontinuation. In addition, comprehensive eye examination identified a new adverse reaction of acquired vitelliform maculopathy in a limited number of patients.
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